Abstract Objectives Technology-assisted treatment (TAT) holds promise for innovative assessment, prevention, and treatment of substance use disorders (SUD). The widespread access to TAT makes it a potentially cost-effective and inventive option available for delivery in multiple settings. This study assessed acceptability of the web-based Therapeutic Education System (TES) in hospitalized dual diagnosis patients with SUDs and other psychiatric disorders. Methods: Eligible participants were nonpsychotic, voluntary patients with self-reported drug or alcohol use in the 30 days prior to admission. They were randomly assigned to treatment as usual (TAU, n = 47) or TAU + TES (n = 48). Acceptability of this Internet-based intervention was assessed by observed utilization and self-report. Results: The TAU + TES group (# analyzed = 41) completed a mean total of 5.5 (SEM = 0.8) modules with about one module per day while hospitalized and rated TES highly on several constructs of acceptability, including novelty, usefulness and ease of understanding. Conclusions: These findings support further exploration of TAT for treatment expansion in a high acuity, dual diagnosis population and indicate the value of future research on efficacy. ClinicalTrials.gov Identifier: NCT02674477

中文翻译：

---

在同时发生物质使用和其他精神疾病的住院患者中进行的基于互联网的治疗的随机和对照可接受性试验

摘要 目标技术辅助治疗 (TAT) 有望为物质使用障碍 (SUD) 的创新评估、预防和治疗带来希望。TAT 的广泛使用使其成为一种潜在的具有成本效益和创造性的选项，可用于在多种环境中交付。本研究评估了基于网络的治疗教育系统 (TES) 在患有 SUD 和其他精神疾病的住院双重诊断患者中的可接受性。方法：符合条件的参与者是在入院前 30 天内自我报告吸毒或酗酒的非精神病、自愿患者。他们被随机分配到照常治疗（TAU，n = 47）或 TAU + TES（n = 48）。这种基于互联网的干预的可接受性是通过观察到的使用情况和自我报告来评估的。结果：TAU + TES 组（# 分析 = 41）在住院期间平均完成了 5.5 个（SEM = 0.8）模块，每天大约一个模块，并对 TES 的几个可接受性结构给予高度评价，包括新颖性、有用性和易于理解。结论：这些发现支持进一步探索 TAT 在高敏锐度、双重诊断人群中的治疗扩展，并表明未来疗效研究的价值。ClinicalTrials.gov 标识符：NCT02674477 双重诊断人群，并表明未来疗效研究的价值。ClinicalTrials.gov 标识符：NCT02674477 双重诊断人群，并表明未来疗效研究的价值。ClinicalTrials.gov 标识符：NCT02674477